Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + olodaterol fixed-dose combination versus free combination in COPD
2015-003879-29Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Trough FEV1 after 28 days of treatment. Started Nov 2015; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-003879-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003879-29.